title: Intervention in gastro-enteropancreatic neuroendocrine tumours.
abstract: Neuroendocrine tumours require dedicated interventions to control their capacity to secrete hormones but also, antitumour growth strategies. Recommendations for early interventions in NET include the management of hormone-related symptoms and poorly differentiated neuroendocrine carcinomas. In contrast, prognostic heterogeneity is a key feature of well differentiated NET that complexified the antitumour strategy whatever the stage in this subgroup of tumour. In this review, timely therapeutic interventions to control hormone-related symptoms and tumour growth in GEP NET patients are discussed. The necessity of controlling hormone-related symptoms as the first step of any strategy affects also the tumour growth control strategy. In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis.
authors.affiliation: Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. baudin@igr.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
authors.forename: David
authors.initials: D
authors.lastname: Planchard
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Joël
authors.initials: J
authors.lastname: Guigay
authors.forename: Clarisse
authors.initials: C
authors.lastname: Dromain
authors.forename: Julien
authors.initials: J
authors.lastname: Hadoux
authors.forename: Thierry
authors.initials: T
authors.lastname: Debaere
authors.forename: Dominique
authors.initials: D
authors.lastname: Elias
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002276:Carcinoid Tumor / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007414:Intestinal Neoplasms / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018358:Neuroendocrine Tumors / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal